Revelation Biosciences Stock Price, News & Analysis

Revelation Biosciences (NASDAQ:REVB) announced an inducement equity grant approved January 8, 2026 of 90,000 restricted stock units (RSUs) to a new non-executive employee. The RSUs were granted outside the company's stockholder-approved equity incentive plan as an inducement under Nasdaq Listing Rule 5635(c)(4). The award vests over two years in equal quarterly installments, beginning on the first quarterly vesting date after the employee's hire date, and is subject to continued service through each vesting date.

Revelation Biosciences (NASDAQ:REVB) announced the initiation of GMP manufacturing for GEMINI and matching placebo to supply later‑stage clinical studies. The manufacturing run will provide clinical drug supply needed to support randomized, double‑blind, placebo‑controlled trials and is described as a critical step toward advancing GEMINI's development and approval pathway.

The company said it is working with a leading global contract manufacturing organization and noted it met with the FDA in December 2025 to seek agency feedback on the clinical development and regulatory pathway for GEMINI as a treatment for acute kidney injury (AKI); Revelation is awaiting the FDA meeting minutes.

Revelation Biosciences (NASDAQ:REVB) announced it has reached a quorum for its Special Meeting on December 3, 2025. Shareholders who have not voted have until 11:59pm ET on December 2, 2025 to submit votes.

The company reaffirmed regulatory progress after successfully submitting and receiving acceptance of an end-of-phase 1 meeting package to FDA on November 20, 2025, and said it remains on track to hold that meeting later in 2025 to discuss the clinical and approval pathway for Gemini for acute kidney injury (AKI). The company also referenced its November 6, 2025 financial report covering the three and nine months ended September 30, 2025, highlighting top-line PRIME clinical results and $9.6 million gross proceeds from a September 2025 warrant inducement.

Revelation Biosciences (NASDAQ:REVB) submitted and had its end-of-phase 1 meeting package accepted by the FDA, and is on track to hold the meeting later in 2025 to get agency feedback on the regulatory pathway for Gemini as a treatment for acute kidney injury (AKI).

The company reported that its Phase 1b PRIME study in stage 3–4 chronic kidney disease met its primary safety and tolerability endpoint and showed reductions in inflammatory activity and restored cellular responses in PBMCs up to 168 hours post-dose. Revelation plans to initiate a later-stage clinical study in 2026 and to publish additional PRIME results while exploring other indications for Gemini.

Revelation Biosciences (NASDAQ:REVB) reported results for the three and nine months ended September 30, 2025, and disclosed corporate and cash updates.

Key points: the company announced top-line PRIME clinical study results, received $9.6 million gross from a September 2025 warrant inducement, and held $12.7 million cash as of September 30, 2025 (up from $6.5 million at December 31, 2024).

Operating highlights include $6.3 million net cash used in operating activities for the nine months ended September 30, 2025 (down from $14.6 million in 2024), a Q3 2025 net loss of $1.9 million (loss per share $(1.77)), and a nine‑month net loss of $6.4 million (loss per share $(9.76)). The company expects cash to fund operations through Q3 2026 and plans to meet with the FDA to align on Gemini’s registration path.

Revelation Biosciences (NASDAQ:REVB) announced the cancellation of the adjourned Special Meeting of Stockholders that had been rescheduled for October 29, 2025 due to a technical difficulty that prevented stockholders from voting all of their shares.

The company set a new record date of October 29, 2025 and scheduled a new Special Meeting for December 3, 2025. Revelation will mail new proxy materials to all stockholders of record as of the new record date and urges stockholders to vote promptly upon receipt.

Revelation Biosciences (NASDAQ:REVB) announced that its 2025 Special Meeting of Stockholders originally convened on October 15, 2025 was adjourned due to insufficient shares present and will reconvene on October 29, 2025 at 12:00 p.m. ET.

The meeting remains virtual via webcast and the record date of September 11, 2025 is unchanged. Stockholders who already voted need not act unless they wish to change their vote; those who have not voted are encouraged to vote before the new meeting date by following the instructions in the proxy materials.

Additional meeting and voting details are available in the company's proxy statement filed with the SEC.

Revelation Biosciences (NASDAQ:REVB) has announced a significant warrant exercise agreement that will generate $9.6 million in gross proceeds. The agreement involves the immediate exercise of 4,355,000 outstanding warrants at $2.20 per share, originally issued on May 29, 2025.

As part of the transaction, exercising holders will receive new Class I warrants to purchase up to 13,065,000 shares of common stock in a private placement. These new warrants will be exercisable at $2.20 per share for five years after stockholder approval. The company will file a resale registration statement within 20 days of closing to register the shares underlying the new warrants.

Revelation Biosciences (NASDAQ:REVB) announced groundbreaking results from its Phase 1b PRIME clinical study of Gemini in stage 3 and 4 chronic kidney disease (CKD) patients. The study met its primary safety endpoint and demonstrated significant efficacy in normalizing inflammatory response at the cellular level.

The trial enrolled 40 patients across 3 US clinics, divided into 5 cohorts. Key findings showed Gemini significantly reduced inflammation in patients with high background PBMC activity and corrected immunoparalysis typical to chronic disease. The drug was well-tolerated at the target dose, with mostly mild adverse events reported.

The company plans an End of Phase 1 meeting with the FDA later this year to discuss program advancement. The results suggest potential breakthrough applications for treating both acute and chronic inflammatory conditions.